» Articles » PMID: 21386935

Utilization of Methylnaltrexone (relistor) for Opioid-induced Constipation in an Oncology Hospital

Overview
Journal P T
Specialty Pharmacology
Date 2011 Mar 10
PMID 21386935
Citations 3
Authors
Affiliations
Soon will be listed here.
Citing Articles

Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department.

Peacock W, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guerin A, Joseph G Adv Ther. 2022; 39(5):2178-2191.

PMID: 35298784 PMC: 9056463. DOI: 10.1007/s12325-022-02090-9.


Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Leppert W Drug Des Devel Ther. 2015; 9:2215-31.

PMID: 25931815 PMC: 4404965. DOI: 10.2147/DDDT.S32684.


Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies.

Sharma A, Jamal M Curr Gastroenterol Rep. 2013; 15(7):334.

PMID: 23836088 DOI: 10.1007/s11894-013-0334-4.

References
1.
. How to reduce prescribing errors. Lancet. 2009; 374(9706):1945. DOI: 10.1016/S0140-6736(09)62104-8. View

2.
Thomas J, Karver S, Cooney G, Chamberlain B, Watt C, Slatkin N . Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358(22):2332-43. DOI: 10.1056/NEJMoa0707377. View

3.
Slatkin N, Thomas J, Lipman A, Wilson G, Boatwright M, Wellman C . Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009; 7(1):39-46. View

4.
Thiel S, Asghar M, Micek S, Reichley R, Doherty J, Kollef M . Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med. 2009; 37(3):819-24. DOI: 10.1097/CCM.0b013e318196206b. View

5.
McMillan S . Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004; 11(3 Suppl):3-9. DOI: 10.1177/10732748040110S302. View